[SCHEDULE 13G/A] COLLEGIUM PHARMACEUTICAL, INC Amended Passive Investment Disclosure

Rhea-AI Filing Summary

PHARMACEUTICAL, INC. ownership disclosure: an amended Schedule 13G/A shows Eventide Asset Management, LLC and co‑filers Finny Kuruvilla, M.D., Ph.D. and Robin C. John each report beneficial ownership of 1,424,282 shares, equal to 4.5% of the class.

The filing lists voting and dispositive power allocations: Eventide reports sole voting and dispositive power over 1,424,282 shares, while Kuruvilla and John report shared voting and dispositive power over the same number. The report is signed on 05/15/2026.

Insights

Institutional Ownership Analyst

Eventide and two individuals report a 4.5% stake via shared/sole control arrangements.

The filing records that Eventide holds 1,424,282 shares with sole voting and dispositive power; Kuruvilla and John report the same share count as shared power. This structure is typical for an investment manager with named principals.

Implications depend on holder intentions; subsequent filings would show changes in position or voting. Voting/disposition split is explicitly disclosed in the report dated 05/15/2026.

Compliance & Governance Specialist

The filers disclaim beneficial ownership under Rule 13d‑4 while disclosing sub‑5% ownership.

The statement includes the Rule 13d‑4 disclaimer and classifies this as "Ownership of 5 Percent or Less of a Class." That designation typically limits reporting obligations and signals a passive or non‑control intent.

Watch for future amendments or Form 13D if ownership or intent changes; the filing gives precise voting/dispositive allocations but does not state trading intentions.

Key Figures

Shares reported: 1,424,282 shares Percent of class: 4.5% CUSIP: 19459J104 +1 more

4 metrics

Shares reported 1,424,282 shares Amount beneficially owned (Eventide, Kuruvilla, John)

Percent of class 4.5% Percent of common stock reported by each filer

CUSIP 19459J104 Issuer CUSIP for Common Stock

Signature date 05/15/2026 Signing date of the amendment

Key Terms

Schedule 13G/A, beneficially owned, Rule 13d-4 disclaimer

3 terms

Schedule 13G/A regulatory

"Amendment No. 8 ) PHARMACEUTICAL, INC Common Stock"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

beneficially owned regulatory

"Amount beneficially owned: (i) Eventide: 1,424,282"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Rule 13d-4 disclaimer regulatory

"In accordance with Rule 13d-4 of the Securities Exchange Act"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 8)

COLLEGIUM PHARMACEUTICAL, INC

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

19459J104

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Eventide Asset Management, LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,424,282.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,424,282.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,424,282.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Finny Kuruvilla, M.D. Ph. D.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,424,282.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,424,282.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,424,282.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP Number(s): 19459J104

1

Names of Reporting Persons

Robin C. John

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 1,424,282.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 1,424,282.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,424,282.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.5 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: COLLEGIUM PHARMACEUTICAL, INC
(b)	Address of issuer's principal executive offices: 100 Technology Center Drive, Stoughton, MA 02072
Item 2.
(a)	Name of person filing: (i) Eventide Asset Management, LLC ("Eventide") (ii) Finny Kuruvilla, M.D., Ph.D. ("Kuruvilla") (iii) Robin C. John ("John")
(b)	Address or principal business office or, if none, residence: Eventide, Kuruvilla and John: One International Place, Suite 4210 Boston, Massachusetts 02110
(c)	Citizenship: Eventide: Delaware Kuruvilla: United States John: United States
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 19459J104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: (i) Eventide: 1,424,282 (ii) Kuruvilla: 1,424,282 (iii) John: 1,424,282
(b)	Percent of class: (i) Eventide: 4.5% (ii) Kuruvilla: 4.5% (iii) John: 4.5%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: (1) Eventide: 1,424,282 (2) Kuruvilla: 0 (3) John: 0
	(ii) Shared power to vote or to direct the vote: (1) Eventide: 0 (2) Kuruvilla: 1,424,282 (3) John: 1,424,282
	(iii) Sole power to dispose or to direct the disposition of: (1) Eventide: 1,424,282 (2) Kuruvilla: 0 (3) John: 0
	(iv) Shared power to dispose or to direct the disposition of: (1) Eventide: 0 (2) Kuruvilla: 1,424,282 (3) John: 1,424,282
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. In accordance with Rule 13d-4 of the Securities Exchange Act of 1934, each of the persons filing this statement expressly disclaim the beneficial ownership of the securities covered by this statement and the filing of this report shall not be construed as an admission by such persons that they are the beneficial owners of such securities.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Eventide Asset Management, LLC

Signature:	/s/ Peter J. Luiso
Name/Title:	Peter J. Luiso, General Counsel
Date:	05/15/2026

Finny Kuruvilla, M.D. Ph. D.

Signature:	/s/ Finny Kuruvilla, M.D., Ph. D.
Name/Title:	Finny Kuruvilla, M.D., Ph. D.
Date:	05/15/2026

Robin C. John

Signature:	/s/ Robin C. John
Name/Title:	Robin C. John
Date:	05/15/2026

Exhibit Information

EXHIBIT 1 - Filed Herewith